]>
IRCT20200722048166N1 IRCT 2021-09-10 Tabriz University of Medical Sciences Atorvastatin and Rosuvastatin in myocardial infarction Comparing the effect of preprocedural loading dose of Arorvastatin vs Rrosuvastatin on prevalence of no-reflow and low TIMI flow in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention 2021-08-02 anticipated 160 Complete https://irct.ir/trial/49776 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, patients are divided into two groups (Atorvastatin & Rosuvastatin) using sealed sachets. The researcher puts drug in the bags and randomly gives one of the sealed bags to each patient, Blinding description: The researcher is the only person who isn't blind in this study. The clinical caregiver randomly delivers packets containing medications to patients. The interventionist monitors and reports outcomes while is unaware of the type of medication that patients are receiving, and the patients are blind to which medication they have received. N/A acute myocardial infarction. Intervention 1: Control group: Patients in this group will be treated Atorostatin 80 mg, the first dose will be prescribed in the emergency department and the other doses will be continuous. Intervention 2: Intervention group: Patients in this group will be treated Resvostatin 40 mg, the first dose will be prescribed in the emergency department and the other doses will be continuous. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information.
public Naser Khalili
Univesity Main St
Tabriz Iran (Islamic Republic of) 5166616471 +98 41 3387 7616 dr_nkhalili@yahoo.com Tabriz University of Medical Sciences scientific Naser Aslan Abadi
Univesity Main St
Tabriz Iran (Islamic Republic of) 5166616471 +98 914 311 0844 dr_nkhalili@yahoo.com Tabriz University of Medical Sciences Iran (Islamic Republic of) All patients who are candidates primary percutaneous intervention with acute myocardial infarction with ST-segment elevation are admitted to the emergency department of Madani heart center of Tabriz. 18 years no limit Both The patients with chronic disease such as inflammatory diseases, renal failure, a history of collagen and vascular disease, current active infection, blood diseases. The patients with history of acute myocardial infarction or ischemic heart disease. The patients with history of diabetes. I21 ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction Treatment - Drugs Treatment - Drugs Control group: Patients in this group will be treated Atorostatin 80 mg, the first dose will be prescribed in the emergency department and the other doses will be continuous. Intervention group: Patients in this group will be treated Resvostatin 40 mg, the first dose will be prescribed in the emergency department and the other doses will be continuous. Rate of no-reflow at the during of PPCI. Timepoint: once at the during of the PPCI. Method of measurement: observational and based on individual skills. Rate of TIMI flow at the end of PPCI. Timepoint: once at the end of the PPCI. Method of measurement: observational and based on individual skills. Rate of mortality. Timepoint: During hospitalization. Method of measurement: Observational. Tabriz University of Medical Sciences Approved 2021-08-02 Ethics committee of Tabriz University of Medical Sciences Golbad Tabriz East Azarbaijan Iran (Islamic Republic of)